RTP Mobile Logo
What Oncology Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Noncolorectal GI Cancers
Released April 2014

Proceedings from Part 2 of a 2-part satellite symposia series during the 2014 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Charles S Fuchs, Pamela L Kunz, J Randolph Hecht, Johanna C Bendell and Alan P Venook. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

    OVERVIEW OF ACTIVITY
    Local and systemic treatment approaches for noncolorectal (non-CRC) GI cancers are continuously evolving. Novel molecular-targeted and biologic therapies have changed best-practice care in some instances (eg, gastric cancer, hepatocellular carcinoma, GI stromal tumors), and late-stage clinical trials have demonstrated evidence of exciting results for additional novel agents that are poised for integration into existing treatment algorithms. Thus, in addition to maintaining a sound understanding of the conventional but distinct treatment algorithms applicable to each subtype of non-CRC GI cancer, practicing oncologists must now rationally integrate targeted agents into their individualized therapeutic recommendations for the safe and effective clinical management of diseases they seldom encounter.

    By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, surgeons and other healthcare providers with the formulation of up-to-date clinical management strategies for various non-CRC GI cancers.

    LEARNING OBJECTIVES

    Upon completion of this activity, participants should be able to:
    • Apply the results of emerging clinical research to the best-practice management of non-CRC GI cancers.
    • Use clinical and molecular biomarkers to select optimal treatment strategies for patients with locally advanced or metastatic gastric or gastroesophageal cancer.
    • Communicate the benefits and risks of existing and emerging local and systemic interventions to patients with locally advanced or metastatic hepatocellular cancer.
    • Assess available and emerging research information to guide treatment decision-making for patients with metastatic GI stromal tumors.
    • Recall new data with investigational agents demonstrating promising activity in non-CRC GI cancers.
    • Counsel patients with non-CRC GI cancers about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Celgene Corporation, Genentech BioOncology, Lilly, Metamark Genetics Inc, Sanofi, Takeda Pharmaceuticals North America Inc; Consulting Agreements: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly.

    Pamela L Kunz, MD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford, California

    Advisory Committee and Stock Ownership: Guardant Health Inc; Contracted Research: Advanced Accelerator Applications, Genentech BioOncology, Lexicon Pharmaceuticals Inc, Merck, Sanofi.

    J Randolph Hecht, MD
    Professor of Clinical Medicine
    Carol and Saul Rosenzweig Chair in
    Cancer Therapies Development
    Director, UCLA GI Oncology Program
    Santa Monica, California

    No real or apparent conflicts of interest to disclose.

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No real or apparent conflicts of interest to disclose.

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Lilly, Onyx Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Incyte Corporation, Lilly, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2014
    Expiration date: April 2015

Acknowledge and close

View video: